Attention! Pharmaceutical companies will be included in the "black list" of these behaviors

On June 5, the State Insurance Administration issued the Guidance on the Establishment of a System of Medical Price and Credit Evaluation for Recruitment (second draft for comments), which proposes to establish a list of pharmaceutical prices and fraud," to carry out credit ratings for pharmaceutical enterprises, to grade the handling of breach of trust, and to disclose to the public, while suspending the eligibility of failed companies for the distribution of winning drugs or medical supplies, and to the public.
in view of the current pharmaceutical industry commercial bribery, market manipulation and other behavior caused by the inflated prices of drugs and medical supplies, medical costs too fast growth, a large loss of medical insurance funds, the draft proposed the establishment of pharmaceutical prices and fraud listinclude, but not limited to, illegal and illegal acts such as pharmaceutical commercial bribery, abuse of dominant position in the market, manipulation of market prices, breach of contract, disruption of procurement order, and violation of integrity and fair competitionFrom the date of the publication of this Opinion, pharmaceutical enterprises (including pharmaceutical and medical supplies production enterprises, distribution enterprises, the same below) in the pricing, bidding, performance, marketing and other processes, through the list of acts listed in the unfair competition, to obtain improper benefits, will be included in the scope of pharmaceutical prices and tender procurement credit evaluationThis also means that pharmaceutical companies will be blacklisted for these actsat the same time, in accordance with the "reliable source, clear conditions, strict procedures, strict operation" requirements, the implementation of credit ratings for pharmaceutical enterprises, according to the nature of the breach of trust, circumstances, timeliness, and the scope of influence and other factors, the pharmaceutical enterprises in the local bidding and procurement market of the breach of trust assessed as general, medium, serious, particularly serious four levels, dynamic updates quarterlythe facts on which the credit rating is based on the act of breach of trust such as pharmaceutical commercial bribery, subject to the decision of the court's decision or the administrative penalty of the law enforcement departmentLocal governments are encouraged to explore the method of quantitative scoring of credit ratings and to continuously improve the standardization of credit ratingsin addition, the hierarchical disposal of breach of trust breachAccording to the credit rating of a pharmaceutical enterprise, the centralized purchasing institution shall take written reminders, prompt the purchaser of risk information, suspend the bidding network of the relevant drugs or medical supplies of the enterprise, suspend the qualification of the successful drug or medical supplies for the distribution of the enterprise, disclose the information of breach of trust to the public and other disposal measures, and compact the pharmaceutical enterprise's liability for breach of trustIf the supply structure of drugs or medical supplies is single and the supply and demand situation is tense, the measures of hierarchical disposal should be taken into account, so as to avoid the absence of clinical treatment means and seriously affect the treatment of patientshowever, the guidance also put forward the establishment of medical enterprises credit automatic repair and active repair mechanismThis is equivalent to giving pharmaceutical companies a chance to correct the breachwith the establishment and promotion of credit evaluation system, pharmaceutical price and credit evaluation system, is conducive to further purifying the order of the pharmaceutical market, optimizing the pharmaceutical business environment, and promoting the high-quality development of the pharmaceutical industryThe State Health Insurance Administration said that in the future, medical institutions will be guided under the same conditions to give priority to the preferential credit rating of pharmaceutical companies as supply or distribution units can be seen, for pharmaceutical companies, in the focus on product quality improvement, but also need to maintain compliance with legal business practices, or may lose access to medical institutions.